Cochlear (ASX:COH) has announced the appointment of Michael Daniell to its board.
Mr Daniell’s appointment will become effective on 1 January 2020. He has worked in the medical device industry for 40 years and has extensive executive leadership experience.
He was managing director and CEO of Fisher & Paykel Healthcare Corporation Limited from November 2001 to March 2016.
Mr Daniell was responsible for the global business and operations including the design, manufacture and marketing of innovative products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea.
Prior to this, Mr Daniell held various technical management and product design roles within Fisher & Paykel Healthcare.
According to Cochlear chair, Rick Holliday-Smith, “Michael has a long and distinguished career in building a globally successful medical device company. His deep experience and expertise in product innovation and leveraging new technologies will be invaluable to the Board. We look forward to his contributions to the continued growth and strategic development of Cochlear.”
Mr Daniell is currently a Non-Executive Director of Fisher & Paykel Healthcare. He is also a Council member of the University of Auckland and a Non-Executive Director of the Medical Research Commercialisation Fund in Melbourne, Australia. Mr Daniell will be a Non-Executive Director and is considered by the Board to be independent. He resides in New Zealand.